The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes by insurance coverage in non-Hodgkin lymphoma (NHL): Experience from two academic centers and a safety-net health system.
 
Yolanda Zhu
No Relationships to Disclose
 
Veronica Leautaud
No Relationships to Disclose
 
Chijioke Nze
No Relationships to Disclose
 
Amy Ayers
No Relationships to Disclose
 
Lorraine Reitzel
No Relationships to Disclose
 
Ya-Chen Shih
Consulting or Advisory Role - Sanofi
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; MorphoSys; Pharmacyclics/Janssen
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Meng Li
Research Funding - Eisai; Lilly